Abstract: Objective：To evaluate and compare the effects and safety of the oxytocin receptor inhibitors and β-receptor agonist in the treatment of premature delivery. Methods：Based on searching the related literatures from the database by computer，we do a comprehensive collection of randomized trial comparing treatments on the oxytocin receptor inhibitor Atosiban and β receptor agonists including Ritodrine，Salbutamol，Terbutaline. Besides，we do Meta-analysis to the clinical research meeting the inclusive criteria，then we use Cochrane Collaboration RevMan 5.0 software for data processing. Results：A total of six literatures has been identified，Atosiban and β-receptor agonist in the extended gestation of 48 h（RR=1.00，95%CI：0.97-1.04，P=0.90），7 d（RR=1.04，95%CI：0.99-1.09，P=0.14），the difference of the above two groups was not statistically significant; There was no significant difference between the Atosiban group and β-receptor agonist group in gestational age at birth（WMD=0.18，95%CI：-0.19-0.55，P=0.34） and the average weight at birth（WMD=-33.89，95%CI：-108.57-40.79，P=0.37）. However，as to tolerability and efficacy，un-delivery within the 48h and requiring no other tocolytic agent（RR=1.07，95%CI：1.01-1.14，P=0.03） and un-delivery within 7 d and needing no other miscarriage drugs（RR=1.25，95%CI：1.14-1.37，P＜0.05） difference of the Atosiban group and β-receptor agonist group was statistically significant; and incidence of side effects in the mother，especially tachycardia has significant difference（RR=0.09，95%CI：0.05-0.17，P＜0.000 01）；differences in the number of discontinuation people due to side effects of maternal between the Atosiban group and β-agonist group was significant（RR=0.08，95%CI：0.05-0.14，P＜0.000 01）. Conclusions：Compared with β-agonist，Atosiban can achieve the similar therapeutic effect in the treatment of premature delivery，however，its tolerance is much stronger than the β-agonist and incidence of side effects in maternal is much less.

Key words: Oxytocin, Premature birth, Meta-analysis, Therapy